Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.
Objective: Our study aimed to assess the effectiveness of esomeprazole or rabeprazole in combination with amoxicillin and clarithromycin for the eradication of Helicobacter pylori in Hong Kong non-ulcer dyspepsia (NUD) patients. Methods: A prospective clinical trial was conducted at the Alice Ho Miu...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 35; no. 3; pp. 343 - 351 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Jun2010
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105196133&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105196133 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02694727 EV4 jtl: Journal of Clinical Pharmacy & Therapeutics issn: 02694727 maglogo: Y pubinfo: dt: Jun2010 vid: 35 iid: 3 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 105196133 2010649943 10.1111/j.1365-2710.2009.01088.x NLM20831535 105196133 ppf: 343 ppct: 8 formats: fmt: @attributes: type: P tig: atl: Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. aug: au: Lee VWY Chau TS Chan AKW Lee KKC Waye MMY Ling TKW Chan FKL affil: School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, China sug: subj: Esomeprazole Administration and Dosage Helicobacter Infections Drug Therapy Pharmacogenetics Rabeprazole Sodium Administration and Dosage Adult Amoxicillin Administration and Dosage Chi Square Test Clarithromycin Administration and Dosage Clinical Trials Confidence Intervals Data Analysis Software Descriptive Statistics Drug Resistance Drug Therapy, Combination Female Fisher's Exact Test Funding Source Hong Kong Human Interviews Male Middle Age Polymorphism, Genetic Treatment Outcomes Adult: 19-44 years Middle Aged: 45-64 years Female Male ab: Objective: Our study aimed to assess the effectiveness of esomeprazole or rabeprazole in combination with amoxicillin and clarithromycin for the eradication of Helicobacter pylori in Hong Kong non-ulcer dyspepsia (NUD) patients. Methods: A prospective clinical trial was conducted at the Alice Ho Miu ling Nethersole Hospital outpatient endoscopy center from June 2004 to December 2005. Participants received amoxicillin 1 g, clarithromycin 500 mg, and, esomeprazole 20 mg (EAC) or rabeprazole 20 mg (RAC), all given twice daily for 1 week. The H. pylori status was determined by the [(13)C] urea breath test at least 4 weeks after completion of the treatment. Mutation status of CYP2C19 in exon 4 and exon 5 associated with the poor metabolizer phenotype was determined. Results: The intention-to-treat eradication rates in patients treated with RAC and EAC were 77% and 84·6% respectively, and per protocol-based eradication rates were 83·7% and 88·9% respectively. The eradication rates did not vary with CYP2C19 phenotype found. For clarithromycin-sensitive strains, the cure rates were statistically significant regardless of CYP2C19 polymorphism ( P < 0·0001). Conclusion: Triple therapy with either EAC or RAC is effective for Hong Kong Chinese NUD patients with H. pylori infection. Success eradication was related to clarithromycin resistance and not CYP2C19 genotype. pubtype: Academic Journal doctype: clinical trial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|